Public trial registry of the CCC-Munich

Trial IMMUTACE

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
IMMUTACE
World
Full title
:

Eine einarmige, offene Phase-II-Studie zur transarteriellen Chemoembolisation (TACE) in Kombination mit Nivolumab bei Hepatozellulärem Karzinom im Zwischenstadium (HCC)

World
Description
:

The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage hepatocellular carcinoma (HCC) as first line therapy.

Die IMMUTACE-Studie bewertet die Sicherheit und Wirksamkeit des Anti-Programmed-Death-1-Antikörpers (Anti-PD-1) Nivolumab in Kombination mit stationären Patienten mit transarterieller Chemoembolisation (TACE) mit multinodulärem Hepatozellulärem Karzinom im Zwischenstadium (HCC) als Erstlinientherapie.

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Medizinische Klinik II, Telefon: 089440072791
Indications
Classification Code Description
ICD-10-GM C22.0 Leberzellkarzinom
- Livertumor
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2023-06-30 / Unknown
Participants
Function Prename Surname Organization